Avidity Biosciences Q3 EPS $(1.27) Misses $(1.11) Estimate, Sales $12.475M Beat $1.932M Estimate
Benzinga Newsdesk 11 months ago
EarningsEarnings BeatsEarnings MissesNews
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.11) by 13.9 percent. This is a 95.38 percent decrease over losses of $(0.65) per share
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.11) by 13.9 percent. This is a 95.38 percent decrease over losses of $(0.65) per share from the same period last year. The company reported quarterly sales of $12.475 million which beat the analyst consensus estimate of $1.932 million by 545.65 percent. This is a 434.03 percent increase over sales of $2.336 million the same period last year.